The additional doses finalize the 600 million dose deal the U.S. government made with Pfizer and BioNTech at the start of the pandemic.
Category: Breaking
1 In 5 Adults Still Reject Covid Vaccines, Poll Finds — Here Are The Biggest Groups Still Holding Out
Republicans, Americans living in rural areas and white evangelical Christians are among the groups most likely to reject the Covid-19 vaccine, according to the Kaiser Family Foundation.
Merck Inks Deal To Share Antiviral Covid Pill With Poorer Countries
The agreement, one of the first to share a critical Covid-19 technology, would allow the drug to be made and sold cheaply in 105 low- and middle-income countries.
Mammoth Biosciences Inks $691 Million Deal To Develop Crispr Gene-Editing Therapies
The deal will see Mammoth partner with Vertex Pharmaceuticals to develop gene-editing therapies to be delivered directly into the body.
Moderna Says Its Covid Shot Generates ‘Strong’ Immune Response In Kids Aged 6-11
The Massachusetts biotech said it plans to submit data to U.S. and European drug regulators in the “near term.”
Covid, Mental Health And High Costs—Here’s What Americans Say Are Their Biggest Health Problems
Two-thirds of Americans think many people in their country can’t afford good healthcare and just a quarter believe everybody gets the same standards of care, compared to global averages of 58% and 39%.
The U.S. Promised 1.1 Billion Covid-19 Vaccine Doses To Poorer Countries. Here’s Where They Are Going.
The White House marked donating 200 million doses Thursday, most of which have been mRNA vaccines produced by Pfizer and Moderna.
Lingering ‘Brain Fog’: Study Finds High Rate Of Cognitive Impairment Months After Covid-19 Infection
High numbers of Covid-19 survivors showed signs of cognitive impairment months after infection, according to tests designed to evaluate memory, language and attention.
Gun Violence Soared In 27 States During The Covid-19 Pandemic — It Went Down In Just One
Rates of gun violence were 30% higher during the pandemic compared to the year before, research found.
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19
The preliminary result comes from the first large clinical trial on Covid-19 booster shots conducted when the delta variant was the prevalent strain.
